secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001818382-24-000153
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA delays ATEV trauma BLA review beyond PDUFA date; Q2 net loss $56.7M
-----------------------------------------------------------------------

- FDA notified Humacyte on Aug 9 that additional time needed to complete ATEV BLA review; PDUFA date was Aug 10; no revised action date yet.
- Q2 net loss $56.7M vs $22.7M YoY, driven by $27.2M non-cash earnout remeasurement and higher R&D costs.
- ATEV V007 Phase 3 trial in hemodialysis showed superior functional patency vs autogenous fistula at 6 and 12 months (p=0.0071).
- Cash $93.6M at June 30, 2024; H1 net cash provided $13.1M from $43M public offering and $20M Oberland draw.
- R&D expense $23.8M (+16% YoY); G&A $5.7M (-8% YoY); no revenue reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838224000153/0001818382-24-000153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838224000153/huma-20240809.htm
  HTML page:      https://secwatch.observer/filing/0001818382-24-000153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer